Physician profile
Eric J Roffman
NPI 1417079674
$5,417.60
in general payments reported to CMS, 2019-2025
29 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $531 · 2021: $184 · 2022: $451 · 2023: $1,142 · 2024: $1,380 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.32 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $831.89 | 2019-2025 | Nucala |
| Genzyme Corporation | $713.01 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $696.43 | 2019-2025 | Dupixent |
| Optinose US, INC. | $512.50 | 2019-2025 | |
| Aerin Medical INC. | $448.03 | 2024-2025 | |
| Intersect Ent, INC. | $439.58 | 2020-2021 | |
| Kaleo, INC. | $339.37 | 2020-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $229.66 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $220.13 | 2019-2023 | Fasenra, Tezspire |
| Grifols USA, LLC | $144.87 | 2020-2024 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $136.74 | 2025 | Neffy |
| Qapel Medical INC | $94.90 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.08 | 2022-2023 | Cuvitru |
| Genentech USA, INC. | $76.89 | 2022-2024 | Xolair |
| Inspire Medical Systems, INC. | $72.00 | 2023-2024 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.46 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $40.08 | 2023-2025 | Ryaltris |
| Medtronic, INC. | $36.37 | 2024 | Propel |
| Teva Pharmaceuticals USA, INC. | $34.56 | 2020 | |
| Ethicon US, LLC | $30.03 | 2022 | |
| Integra Lifesciences Corporation | $29.32 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Phathom Pharmaceuticals, INC. | $28.25 | 2025 | Voquezna |
| Pfizer INC. | $26.01 | 2020 | |
| Blueprint Medicines Corporation | $24.16 | 2023 | Ayvakit |
| Stryker Corporation | $24.12 | 2019 | |
| Hologic Sales and Service, LLC | $16.35 | 2024 | Coolseal Generator |
| Paratek Pharmaceuticals, INC. | $14.76 | 2025 | Xhance |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Roffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.